An interventional study of Neptune and Standard clinical care in Parkinson Disease, sponsored by Copenhagen University Hospital, Rigshospitalet. Active, not recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Copenhagen University Hospital, Rigshospitalet · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Parkinson Disease with a site in Denmark — 12 open to participants now, 18 under way, 1 of them phase 3. Parkinson Disease · Denmark.
Among the 50 studies in Parkinson Disease with a site in Denmark, this one is the 17th largest by planned enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2024, is one of 23 with no phase, reaches primary completion later than 4 of the 17 other live ones, and was the 36th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →12 of the 50 studies in Parkinson Disease with a site in Denmark are open now. Recruiting first, the newest first:
University of Southern Denmark · Sites in Denmark
Ages 18+ · Healthy volunteers
Danish Research Centre for Magnetic Resonance · Sites in Denmark
Ages 18+ · Healthy volunteers
Danish Research Centre for Magnetic Resonance · Sites in Denmark
Ages 18–80
Aarhus University Hospital · Sites in Denmark
Ages 50–80
Hoffmann-La Roche · Sites in Denmark, United States, Australia and 14 more countries
Ages 50–85
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 75 across the 33 interventional studies, 90 across the 17 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 50 have an industry lead sponsor. The 10 most frequent:
Copenhagen University Hospital, Rigshospitalet is the lead sponsor of 46 studies on the registry; 21 are open to participants now.
Copenhagen University Hospital, Rigshospitalet has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Parkinson Disease with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06324422University of AarhusExercise as Treatment of Fatigue in Parkinson´s Disease | 2026-12-01 |
| NCT05981261University of AarhusExperimental Pain in Parkinsons | 2027-01-01 |
| NCT07465107Annemette LokkegaardMotor and Cognitive Exercise in Parkinson's Disease. | 2027-02-14 |
| NCT06570824Danish Research Centre for Magnetic ResonancerTMS as an Intervention for Levodopa-induced Dyskinesia | 2027-05-01 |
| NCT07397377Danish Research Centre for Magnetic ResonanceprTMS as an Intervention for Bradykinesia in Parkinson's Disease | 2027-05-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Parkinson Disease with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall aim of the trial is to compare the efficacy of using wearables and patient-reported outcome measures versus standard care in enhancing the timeliness of referrals to advanced monitoring of treatments for people with Parkinson's Disease.
The study is a multicentre, parallel group, randomized controlled trial, investigating the value of using wearable devices and electronic patient-reported outcome measurements to improve clinical decision-making related to people with Parkinson's Disease.
Data from a wearable device and a mobile app will be compared to current standard of care.
75 participants will be recruited from the uptake area of the Movement Disorder Clinics (MDC) at Rigshospitalet Glostrup (RHG) and 5 private practice neurologists in Denmark. They will equally be randomized to one of two groups: Intervention or Standard of Care.
Each participant will take part of the trial for 6 months, in which they will have 3 study visits:
They will be asked to wear the device for 6 months. We will then compare decisions made related to changes in medication and referrals to advanced treatment.
The criteria were revised on the registry on Oct 20, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention consists of a wrist-worn wearable sensor that tracks motor symptoms and an app for patient-reported outcomes.
Device: Neptune
The control group will wear the wrist-worn wearable sensor, but not be able to view the tracked data.
Other: Standard clinical care
Neptune is a software algorithm that utilizes data from wrist-worn sensors to track Parkinson motor symptoms and displays them in an easy to understand graph. Neptune Care is a mobile app that includes a patient portal, where patients can view their motor data, and a physician portal, where the treating physician can view the objective motor data prior to a clinical visit.
Also known as: Neptune Care
Treatment and management according to standard clinical care
Differences between groups in proportion of patients referred to evaluation for advanced treatment.
Differences in number of referrals based on access to digital measurements
Time frame: 6 months
Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.
Global Sleep Assessment Scale (GSAQ). Every question is scored from 0-3 (highest worst)
Time frame: 6 months
Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.
Non-Motor Symptom Scale (NMSS). Scored from 0-360 (highest worst)
Time frame: 6 months
Changes in type of, frequency and dose of medication (calculated Levodopa Equivalent Dose, LED, by use of Tomlinson's scale)
Levodopa Equivalent Dose, LED, by use of Tomlinson's scale.
Time frame: 6 months
Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.
Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Scored from 0-52 (UPDRS-II), 0-132 (UPDRS-III) and 0-44 (UPDRS-IV) (highest worst)
Time frame: 6 months
Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.
Parkinson's Disease Questionnaire (PDQ-39). Scored from 0-100 (highest worst)
Time frame: 6 months
Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.
EuroQol Questionnaire (EQ5D-5L). Scored from 0-1 and 0-100 (highest best).
Time frame: 6 months
Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.
Patient Global Impressions Scale - Improvement score (measurements of QoL) (PGI-I). Every question is scored from 1-7 (highest worst)
Time frame: 6 months
System Usability Scale
The System Usability Scale (SUS) is a simple, ten-statement questionnaire used to evaluate the usability of a system or product. It is scored from 0-100.
Time frame: Completed at last visit of the study
Referrals
Clinician confidence in referral decision (5-point Likert scale) and reasons for referral
Time frame: 6 months
Medication adjustment
Clinician confidence in changes in oral medication based on wearable data
Time frame: 6 months
Symptom burden
Differences in wearable-based symptom burden (OFF/DYS vs ON time) between groups at the time of referral.
Time frame: 6 months
Referral time
Differences between groups in time from inclusion to referral
Time frame: 6 months
Plan to share: Yes — Study data will be published in anonymized format as supplementary material to publications. Study protocol, SAP, ICF and analytic code will be available upon request.
Supporting information: Study protocol
Time frame: Data will be published as supplementary material to publications.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 24 months is close to that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Oct 2024 → Nov 2024, primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Copenhagen University Hospital, Rigshospitalet